Novo Nordisk reported Phase 3 results showing its combination candidate CagriSema (semaglutide + cagrilintide) reduced blood sugar and produced greater weight loss than semaglutide in patients with type 2 diabetes. The company said the trial met its glycemic primary endpoint and recorded clinically meaningful weight reductions versus Wegovy (semaglutide) in the study population. Data were drawn from more than 2,700 participants over a 68‑week period and included treatment‑regimen estimands to reflect real‑world effectiveness. Novo has already filed for obesity approval and is positioning CagriSema against competing next‑gen metabolic agents, potentially sharpening rivalry with Eli Lilly’s amylin/GLP‑1 competitors.